OR WAIT null SECS
ScinoPharm Taiwan will provide commercial manufacturing of the API topiramate to Supernus Pharmaceuticals.
ScinoPharm Taiwan reports that its Tainan, Taiwan facility is providing commercial manufacturing of the API topiramate for Trokendi XR, a once-daily extended-release formulation of topiramate for the treatment of epilepsy that was developed and recently launched by Supernus Pharmaceuticals in the United States. Supernus received FDA approval to market Trokendi XR in August 2013.
Source: ScinoPharm Taiwan